Kidswell Bio Corporation (4584.T)

138.00 0.00 (0.00%) At close: 03:15PM JST

Kidswell Bio Corporation

Kanayama Building
3rd Floor 1-2-12, Shinkawa Chuo-ku
Tokyo 104-0033
Japan
81 3 6222 9547
https://www.kidswellbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 38

Key Executives

Name	Title	Pay	Exercised	Year Born
Shinya Kurebayashi	President, CEO & Representative Director	N/A	N/A	1976
Yasuyuki Mitani	Chief Scientific Officer	N/A	N/A	N/A
Munechika Sakabe	Chief Manufacturing Officer	N/A	N/A	N/A
Masayuki Kawakami	Corporate Officer of Research & Development Division and Director	N/A	N/A	1964

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease. In addition, its products also include GCT-101 for alveolar cleft; GCT-102 for congenital isolated hypoganglionosis; and other pipeline products for ophthalmologic diseases, cerebral palsy, peripheral nerve palsy, fracture, and spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.

Corporate Governance

Kidswell Bio Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.